- This event has passed.
Cyclerion CY6463 Phase 2a MELAS Study Clinical Data Update
June 28 @ 8:00 am - 9:00 am
MELAS CLINICAL TRIAL UPDATE
Cyclerion CY6463 Phase 2a MELAS Study
Clinical Data Update Webinar
Hosted by UMDF
Tuesday, June 28, 2022
8:00 am EDT
In a webinar hosted by the United Mitochondrial Disease Foundation (UMDF), Cyclerion will discuss promising Phase 2a clinical study of CY6463, a first-in-class CNS- penetrant sGC stimulator, in participants with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS).
Mitochondrial disease clinician-researcher, Amel Karaa, M.D., Assistant Professor and Director of the Mitochondrial Disease Program and Lysosomal Disorders Program at Harvard Medical School and Massachusetts General Hospital, and 2013 UMDF fellow, will discuss the implications and potential future impact of these encouraging data on patients with MELAS.
Click here to read the full press release.
Please save this webinar ZOOM link to your calendar and join us Tuesday, June 28: https://pi.umdf.org/e/346741/j-88460683609/73t51v/494170081?h=T4Sxcel07bcva1syBSr_nMHjp39GTqY_tyjmWBBUins